Global trends in CAR-T cell therapy for multiple myeloma: A bibliometric analysis, 2013–2025
Open Access
- 20 August 2026
- journal article
- research article
- Published by Taylor & Francis in Human Vaccines & Immunotherapeutics
- Vol. 22 (1) , 2711554
Abstract
Multiple myeloma (MM) is the second most common hematological malignancy globally. In 2022, there were approximately 188,000 new cases and 121,000 deaths attributed to MM worldwide. Projections ind...Keywords
This publication has 32 references indexed in Scilit:
- Anti-GPRC5D CAR T-cell therapy as a salvage treatment in patients with progressive multiple myeloma after anti-BCMA CAR T-cell therapy: a single-centre, single-arm, phase 2 trialThe Lancet Haematology, 2025
- Multiple Myeloma: Improved Outcomes Resulting from a Rapidly Expanding Number of Therapeutic OptionsTargeted Oncology, 2025
- Bispecific antibodies and autologous chimeric antigen receptor T cell therapies for treatment of hematological malignanciesMolecular Therapy, 2024
- Allogeneic BCMA-targeting CAR T cells in relapsed/refractory multiple myeloma: phase 1 UNIVERSAL trial interim resultsNature Medicine, 2023
- Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label studyThe Lancet, 2021
- Idecabtagene Vicleucel in Relapsed and Refractory Multiple MyelomaNew England Journal of Medicine, 2021
- Preclinical Evaluation of Allogeneic CAR T Cells Targeting BCMA for the Treatment of Multiple MyelomaMolecular Therapy, 2019
- Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple MyelomaNew England Journal of Medicine, 2019
- ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector CellsTransplantation and Cellular Therapy, 2019
- Software survey: VOSviewer, a computer program for bibliometric mappingScientometrics, 2009